Hosted on MSN1y
Modifying brain molecule relaxin-3 can potentially reduce side effects in treating anxiety, depression and more
When relaxin-3 is released in the brain, it binds to a target receptor RXFP3—to trigger a variety of signaling responses among the cells, which affect the body's physiological processes.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.